ClinicalTrials.gg
Active, not recruitingNCT05624749SIRIUS-SLE 2Updated Oct 14, 2026

Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)

A Phase 3 interventional study of ianalumab and placebo in Systemic Lupus Erythematosus, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 90 sites in 15 countries. Open to participants aged 12 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
288
Allocation
Randomized
Ages
12 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Lupus Erythematosus, Systemic by Novartis — 2 open to participants now, 8 under way, 4 of them phase 3. Lupus Erythematosus, Systemic · Novartis.

Enrollment
4th of 14
288 · median 131
Started
2023
with 2 others
Phase 3
5 of 14
1 open now
Registered
7th of 14
by date

Among the 14 studies in Lupus Erythematosus, Systemic by Novartis, this one is the 4th largest by enrollment, is one of 3 that started in 2023, is one of 5 in phase 3, and was the 7th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

2 of the 14 studies in Lupus Erythematosus, Systemic by Novartis are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 12 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Lupus Erythematosus, Systemic by Novartis, or all of them as a file.
02

Study summary

The trial will evaluate efficacy, safety and tolerability of ianalumab compared to placebo, given as monthly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE).

Read the detailed description

A randomized, double-blind, placebo-controlled multicenter phase 3 study to evaluate efficacy, safety and tolerability of ianalumab on top of standard-of-care therapy in patients with systemic lupus erythematosus (SIRIUS-SLE 2)

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • Systemic Lupus Erythematosus, SLE, B cell depletion, SLEDAI-2K, BILAG-2004, SRI, ANA
04

Who can participate

Ages eligible
12 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants aged 12 years or older at the time of screening, or limited to 18 years or older in European Economic Area countries and other countries where inclusion of participants below 18 years is not allowed.
  • Diagnosis of systemic lupus erythematosus meeting the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) SLE classification criteria at least 6 months prior to screening.
  • Elevated serum titers at screening of anti-nuclear antibodies ≥ 1:80 as determined by a central laboratory with a SLE-typical fluorescence pattern.
  • Currently receiving CS and/or anti-malarial treatment and/or another disease-modifying antirheumatic drug (DMARD) as specified in the protocol.
  • SLEDAI-2K criteria at screening: SLEDAI-2K score ≥ 6 points, excluding points attributed to "fever", "lupus headache", "alopecia", and "organic brain syndrome"
  • BILAG-2004 disease activity level at screening of at least 1 of the following:

    • BILAG-2004 level 'A' disease in ≥ 1 organ system, Or
    • BILAG-2004 level 'B' disease in ≥ 2 organ systems
  • Weigh at least 35 kg at screening

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with ianalumab
  • History of receiving following treatment I) high dose CS, calcineurin inhibitors, JAK or other kinase inhibitors or other DMARD (except as listed in inclusion criteria) administered within 12 weeks prior to screening II) cyclophosphamide or biologics such as immunoglobulins (intravenous or s.c.), plasmapheresis, anti-type I interferon receptor biologic agents, anti-0 agents, CTLA4-Fc Ig or B-cell activating factor (BAFF)-targeting agents administered within 24 weeks prior to screening; belimumab administered within 12 weeks prior to screening. III) any B cell-depleting therapies, other than ianalumab administered within 36 weeks prior to randomization or as long as B cell count is less than the lower limit of normal or baseline value prior to receipt of B cell-depleting therapy (whichever is lower). IV) Traditional Chinese medicines administered within 30 days prior to randomization
  • Active viral, bacterial or other infections requiring intravenous or intramuscular treatment for infection
  • Chronic infection with virus (HBV) or virus (HCV)
  • Evidence of active tuberculosis infection
  • History of primary or secondary immunodeficiency, including a positive (HIV) test result at screening
  • Any one of the following abnormal laboratory values prior to randomization:

    • \< 25000/ mm\^3 (\< 25 x 10\^3/ μL)
    • (Hgb) \< 8.0 g/dL (\< 5 mmol/L), or \< 7.0 g/dL (\< 4.3 mmol/L) if related to participant's SLE such as in active hemolytic anaemia
    • (ANC) (\< 0.8 x 10\^3/ μL)
  • Severe organ dysfunction or life-threatening disease at screening
  • Presence of severe lupus kidney disease as defined by proteinuria above 2 g/day or equivalent using spot urine protein creatinine ratio, or serum creatinine greater than 2.0 mg/dL (176.84 µmol/L), or requiring immune-suppressive induction or maintenance treatment at screening
  • Receipt of live/attenuated vaccine within a 4-week period before first dosing
  • Any uncontrolled, co-existing serious disease, which in the opinion of the investigator will place the participant at risk for participation or interfere with evaluation for SLE-related symptoms
  • Non-lupus conditions such as asthma, gout or urticaria, requiring intermittent or chronic treatment with systemic CS
  • History of of any organ system other than localized basal cell carcinoma of the skin or in situ cervical cancer
  • Pregnant or nursing (lactating) women.
  • Women of (WOCBP), defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of while on study treatment and for 6 months after stopping of drug.
  • Any surgical, medical, psychiatric or additional physical condition that may jeopardize participation in this study
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
288 participants (actual)

Study arms

  • Experimental
    ianalumab s.c. monthly

    ianalumab s.c. monthly

    Drug: ianalumab

  • Placebo comparator
    placebo s.c. monthly

    placebo s.c. monthly

    Drug: placebo

Interventions

  • ianalumab s.c. monthly

    Also known as: VAY736

  • Drugplacebo

    placebo s.c. monthly

06

What researchers measure

Primary outcomes

  1. Proportion of participants achieving Systemic Lupus Erythematosus Responder Index -4 (SRI-4)

    SRI-4 response is defined as: * Systemic Lupus Erythematosus Disease Activity Index - 2000 (SLEDAI-2K) reduction from baseline of ≥ 4 points * No British Isles Lupus Assessment Group-2004 (BILAG-2004) worsening, defined as ≥ 1 new A or ≥ 2 new B items compared to baseline * No worsening in Physician Global Assessment of Disease Activity (PhGA), defined as an increase of ≥ 0.3 from baseline on a 0 to 3 visual analog scale

    Time frame: Week 60

Secondary outcomes

  1. Proportion of participants with no moderate or severe BILAG flare

    Moderate BILAG flare is defined as 2 or more new BILAG-2004 B items compared to the previous visit; severe BILAG flare is defined as 1 or more new BILAG-2004 A items compared to the previous visit

    Time frame: Baseline to Week 60

  2. Proportion of participants maintaining between Week 36 and Week 60 a reduced corticosteroid (CS) dose of predniso(lo)ne ≤ 5 mg/day or ≤ baseline dose, whichever is lower

    Maintaining reduced CS dose from Week 36 to Week 60

    Time frame: Week 36 to Week 60

  3. Proportion of participants achieving BILAG-based Composite Lupus Assessment (BICLA)

    BICLA response is defined as: * Reduction of all baseline BILAG-2004 A to B/C/D and baseline B to C/D and no worsening in other organ systems defined as ≥ 1 new A or ≥ 2 new B items compared to baseline * No worsening from baseline in SLEDAI-2K defined as an increase from baseline of \> 0 points * No worsening in PhGA defined as an increase of ≥ 0.3 from baseline on a 0 to 3 PhGA visual analog scale

    Time frame: Week 60

  4. Proportion of participants achieving Lupus Low Disease Activity State (LLDAS)

    LLDAS response is defined as: * SLEDAI-2K ≤ 4, with no activity in major organ systems (renal, central nervous system (CNS), cardiopulmonary, vasculitis, fever) (Golder et al 2019) * No new lupus disease activity compared with the previous assessment, defined as any new SLEDAI-2K component that was not present at the previous assessment * PhGA (scale 0-3) ≤ 1 * Current predniso(lo)ne (or equivalent) dose ≤ 7.5 mg daily * Well tolerated standard maintenance doses of immunosuppressive drugs and approved biological agents

    Time frame: Week 60

  5. Time to first occurrence of SRI-4

    Time to first occurrence of SRI-4 from baseline to Week 60

    Time frame: Baseline to Week 60

  6. Proportion of participants achieving SRI-4 at Week 60 while maintaining between Week 36 and Week 60 a reduced CS dose of predniso(lo)ne ≤ 5 mg/day or ≤ baseline dose, whichever is lower

    Achieving SRI-4 at Week 60 while maintaining between Week 36 and Week 60 a reduced CS dose of predniso(lo)ne ≤ 5 mg/day or ≤ baseline dose, whichever is lower

    Time frame: Week 36 to Week 60

  7. Proportion of participants achieving SRI-6

    SRI-6 response is defined as: * SLEDAI-2K reduction from baseline of ≥ 6 points * No BILAG-2004 worsening, defined as ≥ 1 new A or ≥ 2 new B items compared to baseline * No worsening in PhGA, defined as an increase of ≥ 0.3 from baseline on a 0 to 3 visual analog scale

    Time frame: Week 60

  8. Proportion of participants achieving SF-36 Bodily Pain response

    Achieving Short Form 36 (SF-36) Bodily Pain response

    Time frame: Week 60

  9. Proportion of participants with Adverse Events (AEs)

    To evaluate safety and tolerability of ianalumab s.c. monthly

    Time frame: Baseline to Week 60

  10. Incidence and titer of anti-drug (ianalumab) antibodies (ADAs) in serum over time

    To evaluate immunogenicity of ianalumab s.c. monthly

    Time frame: Baseline to Week 164

  11. Ianalumab concentration in serum during the treatment and follow-up

    Concentration of Ianalumab in serum

    Time frame: Baseline to Week 164

07

Study locations

90 sites
  • Pinnacle Research Group LLC
    Anniston, Alabama 36207-5710, United States
  • Advanced Medical Research
    La Palma, California 90623, United States
  • University of California LA
    Los Angeles, California 90095, United States
  • Homestead Assoc In Research Inc
    Homestead, Florida 33033, United States
  • IRIS Research and Development
    Plantation, Florida 33324, United States
  • Emory University
    Atlanta, Georgia 30307, United States
  • Willow Rheumatology Wellness
    Willowbrook, Illinois 60527, United States
  • Bluegrass Community Research Inc
    Lexington, Kentucky 40504, United States
  • Accurate Clinical Research
    Lake Charles, Louisiana 70601, United States
  • UMC New Orleans
    New Orleans, Louisiana 70112, United States
  • University Of Maryland
    Baltimore, Maryland 21201, United States
  • Ahmed Arif Medical Research Center
    Grand Blanc, Michigan 48439, United States
  • Washington Univ School Of Medicine
    St Louis, Missouri 63110, United States
  • West Tennessee Research Institute
    Jackson, Tennessee 38305, United States
  • Novel Research LLC
    Bellaire, Texas 77401, United States
  • Novartis Investigative Site
    La Plata, Buenos Aires B1900AWT, Argentina
  • Novartis Investigative Site
    Quilmes, Buenos Aires 1878, Argentina
  • Novartis Investigative Site
    San Miguel, Buenos Aires B1663GKT, Argentina
  • Novartis Investigative Site
    San Miguel, Tucumán Province T4000CBC, Argentina
  • Novartis Investigative Site
    Caba, C1015ABO, Argentina
  • Novartis Investigative Site
    Caba, C1427CCL, Argentina
  • Novartis Investigative Site
    San Miguel de Tucumán, T4000AXL, Argentina
  • Novartis Investigative Site
    Maroochydore, Queensland 4558, Australia
  • Novartis Investigative Site
    St Leonards, 2065, Australia
  • Novartis Investigative Site
    Concepción, Biobio 4070280, Chile
  • Novartis Investigative Site
    Valdivia, Los Ríos Region 5110683, Chile
  • Novartis Investigative Site
    Santiago, RM 7500588, Chile
  • Novartis Investigative Site
    Santiago, Santiago Metropolitan 7500710, Chile
  • Novartis Investigative Site
    Medellín, Antioquia 050001, Colombia
  • Novartis Investigative Site
    Barranquilla, Atlántico 080002, Colombia
  • Novartis Investigative Site
    Barranquilla, Atlántico 080020, Colombia
  • Novartis Investigative Site
    Chía, Cundinamarca 250001, Colombia
  • Novartis Investigative Site
    Bucaramanga, Santander Department 680003, Colombia
  • Novartis Investigative Site
    Cali, Valle del Cauca Department 760046, Colombia
  • Novartis Investigative Site
    Bogotá, 111211, Colombia
  • Novartis Investigative Site
    Montpellier, 34295, France
  • Novartis Investigative Site
    Paris, 75013, France
  • Novartis Investigative Site
    Paris, 75014, France
  • Novartis Investigative Site
    Paris, 75018, France
  • Novartis Investigative Site
    Toulouse, 31054, France
  • Novartis Investigative Site
    Toulouse, 31059, France
  • Novartis Investigative Site
    Tours, 37044, France
  • Novartis Investigative Site
    Freiburg im Breisgau, Baden-Wurttemberg 79106, Germany
  • Novartis Investigative Site
    Cologne, North Rhine-Westphalia 50937, Germany
  • Novartis Investigative Site
    Leipzig, Saxony 04103, Germany
  • Novartis Investigative Site
    Herne, 44649, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    Ahmedabad, Gujarat 380006, India
  • Novartis Investigative Site
    Ahmedabad, Gujarat 380015, India
  • Novartis Investigative Site
    Kozhikode, Kerala 673008, India
  • Novartis Investigative Site
    Kolhāpur, Maharashtra 416001, India
  • Novartis Investigative Site
    Nagpur, Maharashtra 441108, India
  • Novartis Investigative Site
    Nashik, Maharashtra 422101, India
  • Novartis Investigative Site
    Pune, Maharashtra 411001, India
  • Novartis Investigative Site
    Pune, Maharashtra 411007, India
  • Novartis Investigative Site
    New Delhi, National Capital Territory of Delhi 110060, India
  • Novartis Investigative Site
    New Delhi, New Delhi 110029, India
  • Novartis Investigative Site
    Dehradun, Uttarakhand 248001, India
  • Novartis Investigative Site
    New Delhi, 110075, India
  • Novartis Investigative Site
    Ancona, AN 60020, Italy
  • Novartis Investigative Site
    Cona, FE 44124, Italy
  • Novartis Investigative Site
    Padova, PD 35128, Italy
  • Novartis Investigative Site
    Pisa, PI 56126, Italy
  • Novartis Investigative Site
    Roma, RM 00152, Italy
  • Novartis Investigative Site
    Torino, TO 10128, Italy
  • Novartis Investigative Site
    Seremban, Negeri Sembilan 70300, Malaysia
  • Novartis Investigative Site
    Ipoh, Perak 30450, Malaysia
  • Novartis Investigative Site
    Kuala Lumpur, 59100, Malaysia
  • Novartis Investigative Site
    Selangor Darul Ehsan, 68100, Malaysia
  • Novartis Investigative Site
    León, Guanajuato 37160, Mexico
  • Novartis Investigative Site
    Guadalajara, Jalisco 44160, Mexico
  • Novartis Investigative Site
    Mexico City, Mexico City 06700, Mexico
  • Novartis Investigative Site
    Morelia, Michoacán 58000, Mexico
  • Novartis Investigative Site
    Mérida, Yucatán 97000, Mexico
  • Novartis Investigative Site
    Mérida, Yucatán 97070, Mexico
  • Novartis Investigative Site
    México, 07760, Mexico
  • Novartis Investigative Site
    Cluj-Napoca, Cluj 400006, Romania
  • Novartis Investigative Site
    Brasov, 500283, Romania
  • Novartis Investigative Site
    Bucharest, 011172, Romania
  • Novartis Investigative Site
    Gwangju Gwangyeoksi, Gwangju 61748, South Korea
  • Novartis Investigative Site
    Seoul, 04763, South Korea
  • Novartis Investigative Site
    Seoul, 06591, South Korea
  • Novartis Investigative Site
    Kaohsiung City, 833, Taiwan
  • Novartis Investigative Site
    Taichung, 40447, Taiwan
  • Novartis Investigative Site
    Taichung, 407219, Taiwan
  • Novartis Investigative Site
    Taipei, 10002, Taiwan
  • Novartis Investigative Site
    Taipei, 11217, Taiwan
  • Novartis Investigative Site
    Taoyuan, 33305, Taiwan
  • Novartis Investigative Site
    Leeds, West Yorkshire LS7 4SA, United Kingdom
  • Novartis Investigative Site
    Doncaster, DN2 5LT, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Apr 2027, 47 months after the start.

Of 53 phase 3 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 84. This study's planned 47 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2022
First posted
Nov 22, 2022
StartActual
Apr 21, 2023
Primary completionEst.
Apr 12, 2027
CompletionEst.
Apr 9, 2029
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05624749
Responsible party
Sponsor
First posted
Nov 22, 2022
Start date
Apr 21, 2023
Primary completion
Apr 12, 2027 (estimated)
Completion
Apr 9, 2029 (estimated)
Last update
Oct 14, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ianalumab

Start the discussion